



RHYTHMIA MEDICAL AND ENDOSENSE ANNOUNCE JOINT DEVELOPMENT AGREEMENT TO INTEGRATE ADVANCED 3-D MAPPING AND FORCE CONTROL IN SYSTEM TO TREAT CARDIAC ARRHYTHMIAS

BURLINGTON, Mass. and GENEVA – May 4, 2011 – [Rhythmia Medical Inc.](#) and [Endosense](#) have engaged in a joint development project to integrate the contact-force data provided by Endosense’s [TactiCath® force-sensing ablation catheter](#)¹ into Rhythmia’s advanced three-dimensional cardiac mapping, visualization and navigation system. The project’s objective is to build on earlier feasibility tests to develop an integrated solution that allows electrophysiologists to quickly, efficiently and effectively view catheter tip-to-tissue contact force on a high-resolution, 3-D electro-anatomical map.

The joint development project brings together two recognized innovators in the catheter ablation treatment of cardiac arrhythmias. Rhythmia Medical is pioneering new technology to allow for fast, simple and accurate 3-D mapping of electrical heart activity. Endosense pioneered the field of contact-force sensing with its TactiCath force-sensing ablation catheter and accompanying TactiSys system¹. By integrating their technologies, Rhythmia Medical and Endosense intend to provide electrophysiologists with an exceptional user experience to improve the patient outcomes of cardiac ablation procedures.

“By building Endosense’s contact-force sensing capability into Rhythmia Medical’s open platform advanced 3-D mapping, visualization and navigation system, we have the potential to deliver a new solution that will enhance the value of 3D mapping with the greater insight and control of force-sensing into the EP lab,” said Leon Amariglio, co-chief executive officer of Rhythmia. “We are excited to be partnering with an industry leader and pioneer like Endosense to bring these significant benefits to electrophysiologists and their patients.”

Eric Le Royer, chief executive officer, Endosense, also commented on the development project. “We expect our joint effort with Rhythmia to yield a compelling new tool for electrophysiologists, as it will marry two very complementary, state-of-the-art technologies aimed at improving the efficacy, safety and ease of performing cardiac ablation procedures. I have witnessed the benefits of the speed, accuracy and ease of use of the Rhythmia system during the earlier pre-clinical feasibility tests we conducted together. We are happy to

partner with this innovative company as part of our open platform strategy to integrate value-added contact-force sensing capability into advanced 3D mapping systems.”

About Endosense

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact-force measurement in catheter ablation with the development of the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Launched in April 2010 with a full release in September 2010, the second generation of the novel device has been used across Europe to treat more than one thousand patient cases of atrial fibrillation (AF) and supraventricular tachycardia (SVT). Endosense is currently conducting several post-market clinical studies aimed at proving the superiority of the TactiCath force-sensing catheter over standard irrigated catheters, as well as the TOCCASTAR investigational device exemption (IDE) clinical trial. The company is also executing an open platform strategy to integrate its technology into a range of three-dimensional cardiac mapping systems. BIOTRONIK is the exclusive distributor of the TactiCath in Europe, Latin America, Canada, Africa and the Middle East.

Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit www.endosense.com.

About Rhythmia Medical Inc.

Founded in 2004, Rhythmia Medical Inc. is developing a next generation mapping, visualization and navigation system for the treatment of cardiac arrhythmias. The company recently began human clinical testing outside the United States and is working with several of the leading clinicians in this field around the world. Results of the initial clinical testing will be presented at HRS 2011. The Burlington, Mass.-based company has raised \$19 million in financing from numerous investors, including leading medical device venture capital firm Norwich Ventures. Additional information can be found at www.rhythmia.com.

¹Caution: In the United States, the TactiCath is an investigational device. Limited by Federal (or United States) law to investigational use.

RHYTHMIA MEDIA CONTACT:

Leon Amariglio

(1) 617 591 9191

la@rhythmia.com

ENDOSENSE MEDIA CONTACT/U.S.:

Laura Nobles

Nobles Communications

310-795-0497

laura@noblescommunications.com

ENDOSENSE MEDIA CONTACT/EUROPE:

Danièle Castle

Genevensis Communications

+41 79 202 6667

info@genevensis.com